Personality disorders among Spanish prisoners starting hepatitis C treatment: Prevalence and associated factors.

Autor: Marco A; Health Services of Barcelona Men's Penitentiary Centre, Barcelona, Spain., Antón JJ; Health Services of Albolote Penitentiary Centre, Granada, Spain., Saiz de la Hoya P; Health Services of Fontcalent Penitentiary Centre, Alicante, Spain., de Juan J; Health Services of Córdoba Penitentiary Centre, Córdoba, Spain., Faraco I; Health Services of Sevilla Penitentiary Centre, Sevilla, Spain., Caylà JA; Epidemiology Service, Public Health Agency of Barcelona, CIBER de Epidemiología y Salud Pública (CIBERESP), Spain., Trujols J; Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Sant Pau Biomedical Research Institute (IIB Sant Pau), CIBER de Salud Mental (CIBERSAM), Barcelona, Spain. Electronic address: jtrujols@santpau.cat.
Jazyk: angličtina
Zdroj: Psychiatry research [Psychiatry Res] 2015 Dec 30; Vol. 230 (3), pp. 749-56. Date of Electronic Publication: 2015 Nov 10.
DOI: 10.1016/j.psychres.2015.11.016
Abstrakt: The purpose of this study was to assess the prevalence of personality disorders (PDs) and their associated factors in prisoners who initiate chronic hepatitis C (CHC) treatment in 25 Spanish prisons. The Personality Diagnostic Questionnaire-4 was used to diagnose PDs according to DSM-IV criteria. Factors potentially associated with a PD diagnosis were evaluated by logistic regression analysis. Two hundred and fifty-five patients were initially assessed and 62 (24.3%) were excluded due to an incomplete or invalid self-report screening questionnaire. PD prevalence was 70.5%, with antisocial PD being the most prevalent (46.1%). In terms of PD clusters, the most prevalent was cluster-B (55.4%). PD diagnosis was associated with HCV genotypes 1, 2, or 3 (odds ratio [OR] 2.14, 95% confidence interval [CI] 1.02-4.49). Patients with a cluster-B PD were more likely to be infected with HCV genotypes 1, 2, or 3 (OR 2.37, 95% CI 1.08-5.23) and be HIV-infected (OR 2.20, 95% CI 1.10-4.39), to report past-year injection drug use (OR 7.17, 95% CI 1.49-34.58), and to have stage 3 or 4 fibrosis (OR 2.16, 95% CI 1.06-4.49). The prevalence of PDs in Spanish prisoners who initiate CHC treatment is very high. PD management issues should be considered in treating CHC patients in prisons.
(Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: